Cardiol Therapeutics (CRDL) Net Income towards Common Stockholders (2020 - 2026)

Cardiol Therapeutics (CRDL) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$6.9 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 21.58% year-over-year to -$6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20.4 million (up 6.05% YoY) and the FY2025 annual result came in at -$24.1 million, up 13.91% from the prior year.
• Net Income towards Common Stockholders improved to -$6.9 million in Q1 2026, from -$7.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$4.7 million in Q2 2023 to a low of -$10.4 million in Q3 2024.
• A 5-year average of -$6.9 million and a median of -$6.3 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders surged 43.66% — and 2024, when it tumbled 81.51%.
• Tracing CRDL's Net Income towards Common Stockholders over 5 years: stood at -$6.4 million in 2022, then increased by 10.51% to -$5.7 million in 2023, then plunged by 81.51% to -$10.4 million in 2024, then increased by 28.64% to -$7.4 million in 2025, then climbed by 6.29% to -$6.9 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$6.9 million (Q1 2026), -$7.4 million (Q3 2025), and -$6.1 million (Q2 2025), per Business Quant data.